


Regression of aneurysmal type 1 neovascularization after brolucizumab injections



A 68-year-old man presented with progressive visual acuity decline OS. Optical coherence tomography revealed an irregular pigment epithelial detachment (PED) and a ring-like lesion enclosed in a peaked PED (inlet) with intra- and subretinal fluid (A). Early-phase indocyanine green angiography showed a branching vascular network (BVN) with an aneurysmal dilation (arrowhead) at the temporal margin of the BVN (B). One month after 2 brolucizumab intravitreal injections, complete resorption of fluid, flattening of the PED, and disappearance of the aneurysmal dilation were observed (C, D), along with reduced vascular density of the BVN. Brolucizumab could have a prominent role in the management of aneurysmal type 1 neovascularization. **Fig.**

Q1 Matteo Airaldi,*
Mariano Cozzi,*
Giovanni Staurenghi*

*Eye Clinic, Department of Biomedical and Clinical Science “Luigi Sacco”, University of Milan, Milan, Italy.

Originally received May. 17, 2021. Final revision Jul. 13, 2021. Accepted Sep. 7, 2021.

Correspondence to:

Matteo Airaldi, Eye Clinic, Department of Biomedical and Clinical Science “Luigi Sacco”, University of Milan, Milan, Italy.; matteo.m.airaldi@gmail.com.

Q2

Footnotes and Disclosure

The authors declare the following financial interests/personal relationships that may be considered potential competing interests: Matteo Airaldi: none; Mariano Cozzi: Nidek and Bayer; and Giovanni Staurenghi: Heidelberg Engineering, Optos, Centervue, Zeiss, Bayer, Apellis Pharmaceuticals, Allergan, Astellas, Boehringer Ingelheim, Genentech, Graybug, Novartis, Roche, Chengdu Kanghong Biotech, Kyoto Drug Discovery and Development, Biogen, and Ocular Instruments.

Q3